Loading... Please wait...
Sort by:
  • Prostate Cancer: Update Bulletin [May 2016]
    Learn More Prostate Cancer: Update Bulletin [May 2016]
    Gain new KOL insights on the latest events with the potential to shape the targeted treatment of prostate cancer. Topics covered include opinions about Astellas and Medivation’s Phase III ARCHES trial of Xtandi...
  • Ulcerative Colitis: Update Bulletin [May 2016]
    Learn More Ulcerative Colitis: Update Bulletin [May 2016]
    Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include the FDA’s approval of Celltrion’s Inflectra in April 2016, as well as the positive recommendation from the...
  • Head and Neck Squamous Cell Carcinoma: Update Bulletin [May 2016]
    Learn More Head and Neck Squamous Cell Carcinoma: Update Bulletin [May 2016]
    Gain new KOL insights on the latest events with the potential to shape the targeted treatment of head and neck squamous cell carcinoma (HNSCC). Topics covered include opinions about the US FDA priority review granted for...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Who will benefit most from huge opportunities in NASH treatment? The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which...
  • Breast Cancer: KOL Insight
    Learn More Breast Cancer: KOL Insight
    Targeted therapies deliver on promise to transform breast cancer treatment Targeted therapies continue to transform breast cancer treatment—branching out into new settings, targeting new patient populations, and...
  • COPD: KOL Insight
    Learn More COPD: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the COPD market. Topics covered include; Novartis’ December 2016 publication of positive results from the CRYSTAL study,...
  • NSCLC: Update Bulletin [April 2016]
    Learn More NSCLC: Update Bulletin [April 2016]
    Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about the FDA advisory committee vote against approval...
  • Targeted Therapies In Asthma: Update Bulletin [April 2016]
    Learn More Targeted Therapies In Asthma: Update Bulletin [April 2016]
    This edition presents key opinion leader (KOL) views on recent developments in the asthma market, including the clinical role of Nucala (mepolizumab; GSK) the prospects for Teva’s recently approved Cinqair...
  • Malignant Melanoma: Update Bulletin [April 2016]
    Learn More Malignant Melanoma: Update Bulletin [April 2016]
    Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF...
  • Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
    Learn More Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
    Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of Type 2 Diabetes Mellitus (T2DM). Topics covered include expert opinions on the positive data reported by Novo...
  • Psoriasis: Update Bulletin [April 2016]
    Learn More Psoriasis: Update Bulletin [April 2016]
    Gain new KOL insights on the latest events happening in plaque psoriasis. Topics covered include opinions regarding several biosimilar anti-TNFs, including Samsung Bioepis’ Benepali (etanercept) and Flixabi...
  • Dyslipidaemia: KOL Insight
    Learn More Dyslipidaemia: KOL Insight
    Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have relegated them to...
  • Cancer Immunotherapy: Update Bulletin [March 2016]
    Learn More Cancer Immunotherapy: Update Bulletin [March 2016]
    In this update, payers offer their views on the recent reform of the cancer drugs fund (CDF) and its impact on access to cancer immunotherapies in the UK. In light of the impressive data recently released for Juno...
  • Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]
    Learn More Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]
    Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about Gilead’s suspension of a Phase II trial of simtuzumab; Boehringer Ingelheim’s...
  • Multiple Sclerosis: Update Bulletin [March 2016]
    Learn More Multiple Sclerosis: Update Bulletin [March 2016]
    Gain new KOL insights on the latest events happening in multiple sclerosis (MS):Topics covered include opinions about the discontinuation of Teva’s/Active Biotech’s higher-dose laquinimod Phase III studies;...
  • Psoriasis: Update Bulletin [January 2016]
    Learn More Psoriasis: Update Bulletin [January 2016]
    Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of moderate to severe plaque psoriasis. Topics covered include opinions about ixekizumab (Eli Lilly) and if safety...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved